Abstract
The novel, long-acting local anesthetics (LAs) ropivacaine and levobupivacaine were developed to offer a safer alternative to bupivacaine. The well-known toxic effects of bupivacaine on the central nervous system and the cardiovascular system seem to be less severe when comparable plasma levels of these pure levorotatory agents are reached. Although there is evidence of greater safety in the experimental setting, its actual impact on clinical practice remains unclear. Randomized, controlled trials using clinical endpoints have shown that the enantiomeric LAs are viable alternatives to bupivacaine, and may offer advantages in some settings where a greater differentiation between motor and sensory block may become evident. The available evidence seems to support the use of the novel LAs over bupivacaine whenever large doses are used or the risk of unintended intravascular injection is high, such as in continuous epidural analgesia or peripheral nerve blocks.
Keywords: Bupivacaine, levobupivacaine, ropivacaine, local anesthetics, peripheral nerve block, regional anesthesia techniques
Current Drug Therapy
Title: Enantiomeric Local Anesthetics: Can Ropivacaine and Levobupivacaine Improve Our Practice?
Volume: 1 Issue: 1
Author(s): Andrea Casati and Marco Baciarello
Affiliation:
Keywords: Bupivacaine, levobupivacaine, ropivacaine, local anesthetics, peripheral nerve block, regional anesthesia techniques
Abstract: The novel, long-acting local anesthetics (LAs) ropivacaine and levobupivacaine were developed to offer a safer alternative to bupivacaine. The well-known toxic effects of bupivacaine on the central nervous system and the cardiovascular system seem to be less severe when comparable plasma levels of these pure levorotatory agents are reached. Although there is evidence of greater safety in the experimental setting, its actual impact on clinical practice remains unclear. Randomized, controlled trials using clinical endpoints have shown that the enantiomeric LAs are viable alternatives to bupivacaine, and may offer advantages in some settings where a greater differentiation between motor and sensory block may become evident. The available evidence seems to support the use of the novel LAs over bupivacaine whenever large doses are used or the risk of unintended intravascular injection is high, such as in continuous epidural analgesia or peripheral nerve blocks.
Export Options
About this article
Cite this article as:
Casati Andrea and Baciarello Marco, Enantiomeric Local Anesthetics: Can Ropivacaine and Levobupivacaine Improve Our Practice?, Current Drug Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157488506775268506
DOI https://dx.doi.org/10.2174/157488506775268506 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Risk Factors for Delirium after Cardiac Surgery: A Review
Current Neuropharmacology Use of Nanoparticles as Therapy for Methicillin-Resistant Staphylococcus aureus Infections
Current Drug Metabolism Discovery and ADMET: Where Are We Now
Current Topics in Medicinal Chemistry Diterpenes: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results
Current Cardiology Reviews Deletion of Endoplasmic Reticulum Stress-Induced CHOP Protects Microvasculature Post-Spinal Cord Injury
Current Neurovascular Research Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases
Current Pharmaceutical Design Ezogabine: Development and Role in the Management of Epileptic Seizures
Mini-Reviews in Medicinal Chemistry The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Use of Dopaminergic Agents in the Treatment-Resistant Depression
Current Psychopharmacology Peptides in Oral Diseases
Current Pharmaceutical Design Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension
CNS & Neurological Disorders - Drug Targets An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Kv1.5 Blockers for the Treatment of Atrial Fibrillation: Approaches to Optimization of Potency and Selectivity and Translation to In Vivo Pharmacology
Current Topics in Medicinal Chemistry Synthesis of Some New Chromeno[2,3-b]pyridine and [1,2,4]Triazolo[1,5- a]quinoline Nucleoside Analogues with Expected Biological Activity
Letters in Organic Chemistry Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Therapy in Prion Diseases
Current Topics in Medicinal Chemistry